Time-dependent dose guided radiotherapy (DGRT) with ... - Varian
Time-dependent dose guided radiotherapy (DGRT) with ... - Varian
Time-dependent dose guided radiotherapy (DGRT) with ... - Varian
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Time</strong>-<strong>dependent</strong> <strong>dose</strong> <strong>guided</strong> <strong>radiotherapy</strong> (<strong>DGRT</strong>) <strong>with</strong><br />
electronic portal imaging as a patient QA and research tool<br />
S Nijsten, M Podesta, L Persoon, W van Elmpt,<br />
F Verhaegen<br />
MAASTRO Clinic, Maastricht, the Netherlands<br />
1
Dose Guided RadioTherapy (<strong>DGRT</strong>):<br />
measuring true daily patient <strong>dose</strong><br />
2
What is the place of <strong>DGRT</strong> in the <strong>radiotherapy</strong> chain?<br />
<strong>DGRT</strong><br />
IGRT 3
MAASTRO <strong>DGRT</strong> Philosophy<br />
You need to know the true daily delivered 3D <strong>dose</strong><br />
You need to know the true delivered total 4D <strong>dose</strong> over the treatment<br />
(possibly also 4D <strong>dose</strong> rate)<br />
H<br />
O<br />
W<br />
?<br />
Combine all your verification imaging tools<br />
Develop new verification imaging tools/methods<br />
Make these tools/methods fast<br />
With all the information collected, develop optimum methods for ART<br />
Integrate in clinic<br />
4
• EPI dosimetry<br />
<strong>DGRT</strong> <strong>with</strong> EPI<br />
– Point <strong>dose</strong> (1D) verification<br />
– Pre-treatment 2D <strong>dose</strong> verif (no pt)<br />
– Transit 2D <strong>dose</strong> verif (+ pt)<br />
– Pre-treatment 3D <strong>dose</strong> verif (no pt)<br />
– Transit 3D <strong>dose</strong> verif (+ pt)<br />
– Pre-treatment time-<strong>dependent</strong> 2D <strong>dose</strong> verif (no pt)<br />
– Transit time-<strong>dependent</strong> 2D <strong>dose</strong> verif (+ pt)<br />
EPID<br />
patient<br />
EPID<br />
– In-vivo time-<strong>dependent</strong> 3D <strong>dose</strong> verif (+ pt) = 4D EPID dosimetry<br />
• Daily pt imaging (Cone beam CT, 3/4DUS, image<br />
registration)<br />
• Decision tools for Adaptive RT<br />
• Trials<br />
5
Four components of 2-D EPID dosimetry<br />
Pre-treatment<br />
<strong>dose</strong> prediction<br />
Transit<br />
<strong>dose</strong> prediction<br />
EPID<br />
dosimetry<br />
Gamma<br />
calculation<br />
EPI <strong>dose</strong><br />
conversion<br />
6
Gamma<br />
calculation<br />
Original distribution<br />
(γ from 0 to 1)<br />
Gamma calculation and visualisation<br />
(� criterion of 3%, 3 mm)<br />
Dose difference coding<br />
(γ from -1 to 1)<br />
Pass/fail coding<br />
EPID measures more <strong>dose</strong><br />
EPID measures less <strong>dose</strong><br />
7
8<br />
30-70x faster
Pre-treatment<br />
<strong>dose</strong> verification<br />
Verification I: Pre-treatment <strong>dose</strong> verification<br />
(S Nijsten, W van Elmpt et al., Med. Phys. 34, 2007)<br />
� detect errors in transfer between<br />
TPS and linac<br />
� detect malfunctioning of linac<br />
(machine output variations, MLC errors,<br />
beam flatness…)<br />
9
Pre-treatment<br />
<strong>dose</strong> verification<br />
Pre-treatment <strong>dose</strong> verification for IMRT of H&N<br />
(� criterion of 5%, 5 mm)<br />
Predicted PDI Measured PDI Pre-treatment �<br />
Before the start of treatment, for every patient the treatment fields are delivered and<br />
measured <strong>with</strong> the EPID<br />
10
Transit <strong>dose</strong><br />
verification<br />
Verification II: Transit <strong>dose</strong> verification<br />
(W van Elmpt, S Nijsten et al., Med. Phys. 32, 2005)<br />
(S Nijsten, W van Elmpt et al., Med. Phys. 34, 2007)<br />
� detect patient-related delivery errors<br />
(set-up errors, organ motion, weight loss,<br />
changes in fixation, …)<br />
11
Transit <strong>dose</strong><br />
verification<br />
No pt in beam<br />
+ pt in beam<br />
Predicted pretreatment<br />
PDI<br />
Transit dosimetry for tongue cancer treatment<br />
(� criterion of 5%, 5 mm)<br />
Measured pretreatment<br />
PDI Pre-treatment �<br />
Predicted transit<br />
Measured transit<br />
Transit �<br />
PDI PDI<br />
12
Five components of 3-D EPID dosimetry<br />
3-D in-vivo<br />
<strong>dose</strong> verification<br />
Pre-treatment<br />
<strong>dose</strong> verification<br />
EPID<br />
dosimetry<br />
Dose<br />
recalculation<br />
3-D image<br />
acquisition<br />
CBCT<br />
EPI <strong>dose</strong><br />
conversion<br />
13
It is possible to distinguish beam and patient related<br />
delivery errors (Using only 3D transit <strong>dose</strong> reconstruction)<br />
Beam delivery error<br />
MLC error<br />
Patient related delivery error<br />
decrease in lung fluid + setup error<br />
1<br />
2<br />
Planning CT Repeat CT or CBCT<br />
= representation of<br />
pt today<br />
Backprojection<br />
through pt<br />
Detection of<br />
composite<br />
delivery errors<br />
2<br />
2<br />
Detection of<br />
beam<br />
delivery errors only<br />
2<br />
1<br />
14
Axial<br />
Coronal<br />
Sagittal<br />
Beam and patient related delivery errors<br />
(Reconstructed 3D <strong>dose</strong> distributions)<br />
Prescribed 3D <strong>dose</strong> in TPS<br />
3D <strong>dose</strong> <strong>with</strong><br />
beam delivery errors only<br />
3D <strong>dose</strong> <strong>with</strong><br />
patient related delivery errors only<br />
15
<strong>Varian</strong> TrueBeam<br />
Volumetric Modulated Arc Therapy (VMAT):<br />
<strong>Time</strong>-resolved (4D) dosimetry<br />
DRR per control point<br />
Transit <strong>dose</strong> per control point<br />
16
VMAT: <strong>Time</strong>-resolved EPID images<br />
(=‘fluoroscopy’)<br />
<strong>Time</strong>-resolved EPID during treatment:<br />
�allows investigating causes of differences between predicted<br />
and measured <strong>dose</strong><br />
<strong>Time</strong> series (‘film’)<br />
17
Pre-treatment <strong>dose</strong> prediction; per control point<br />
Fluence map<br />
Predicted<br />
primary PDI<br />
Predicted EPI<br />
scatter PDI<br />
EPID<br />
+ =<br />
Pre-treatment<br />
Predicted total pretreatment<br />
PDI<br />
18
Pre-treatment <strong>dose</strong> prediction; integrated over 1 beam direction<br />
Fluence map<br />
Predicted<br />
primary PDI<br />
Predicted EPI<br />
scatter PDI<br />
EPID<br />
+ =<br />
Pre-treatment<br />
Predicted total pretreatment<br />
PDI<br />
19
Transit <strong>dose</strong> prediction; integrated over 1 beam direction<br />
Predicted<br />
primary PDI<br />
Predicted<br />
scatter PDI<br />
+ =<br />
Predicted total<br />
transit PDI<br />
20
One control point<br />
Gamma calculation<br />
Integrated <strong>dose</strong><br />
21
<strong>Varian</strong> Research project: <strong>Time</strong>Port<br />
<strong>Time</strong>-resolved pre-treatment 2D portal dosimetry<br />
• Dosimetry verification of RapidArc treatment (+FFF)<br />
• Hypothesis: Beam delivery <strong>with</strong> a <strong>Varian</strong> RapidArc linac can, pretreatment,<br />
be verified accurately and fast <strong>with</strong>out the need for<br />
phantom measurements using time-resolved EPID dosimetry<br />
Total accumulated calculated portal<br />
<strong>dose</strong> for entire arc treatment<br />
Measured total portal image<br />
22
Clinical workflow for routine treatment verification<br />
@ MAASTRO CLINIC – EPICORE SYSTEM (3D)<br />
23
Planning CT<br />
Second CT<br />
Before fx 4<br />
Third CT<br />
Before fx 18<br />
Application:Trends in <strong>dose</strong> discrepancies;<br />
A lung cancer case<br />
24
Monitoring <strong>dose</strong> delivery over the whole treatment<br />
course<br />
CT2 fraction (#) PLAN 2<br />
CT3<br />
field (#)<br />
field (#)<br />
4 5 6 7 8 9<br />
fraction (#) PLAN 3<br />
18 19 20 21 22 23<br />
4 8 12 16 20 24<br />
18<br />
40<br />
20 25 30 35<br />
25
A side story: <strong>DGRT</strong> on small animal irradiation/imaging system<br />
(pre-clinical)<br />
15 x 1mm<br />
beams<br />
Predicted EPI Measured EPI �(5%,0.8mm)<br />
26
Conclusions & Outlook<br />
• DGTR provides powerful tools for decision making in<br />
adaptive RT<br />
– 2D pre-treatment/transit dosimetry<br />
– 3D pre-treatment/transit dosimetry<br />
– Separate machine from patient errors<br />
– Separate systematic from random patient errors<br />
• Ongoing:<br />
– <strong>Time</strong>-resolved EPI dosimetry (‘4D’)<br />
– Clinical integration<br />
– Patient data analysis for different cancer sites<br />
– Decision models 27